Moderna

Develops mRNA-based medicines for health

Cambridge, Massachusetts, United States

About Moderna

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a crucial component in how cells produce proteins necessary for biological functions. Their approach involves creating a new class of medicines that utilize mRNA to instruct cells to produce specific proteins, potentially leading to significant advancements in treating diseases. Unlike traditional pharmaceuticals, which often rely on chemical compounds, Moderna's mRNA-based therapies aim to enhance the discovery, development, and manufacturing processes of medicines. The company's goal is to improve patient outcomes by harnessing the power of mRNA to create effective treatments.

Cambridge, MassachusettsHeadquarters

2010Year Founded

$5,925.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

5,001-10,000Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

Sabbatical Leave

Hybrid Work Options

401(k) Company Match

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Risks

Potential backlash in Australia for bypassing vaccine safety steps.

Possible removal from Nasdaq 100 Index could affect investor confidence.

Hong Kong residents' reluctance to get vaccinated may hinder market penetration.

Differentiation

Moderna is pioneering mRNA technology for new categories of medicines.

The company integrates AI to optimize mRNA design and production processes.

Moderna's mRNA platform enables rapid development of vaccines and therapeutics.

Upsides

Moderna received a $176 million contract for a bird flu vaccine.

The company is expanding mRNA applications to personalized cancer vaccines.

Moderna is establishing a domestic mRNA production facility in Australia.

Funding

Total raised$5.93 B

Latest valuation$7.50 B

StageIPO

GRANT

6/30/2024

$176

POST IPO EQUITY

2/29/2024

$750

IPO

11/30/2018

$604

$7.50 B

SERIES H

4/30/2018

Merck

$125

$625.00 M

SERIES G

1/31/2018

$500